VP of Product Development Dorothy “Dot” Colagiovanni
Devising next-generation products geared towards the unmet needs of non-traditional cannabis consumers.
“I like to think that we’re a part of ‘Cannabis 2.0’ at this point,” says Colagiovanni.
Colagiovanni considers “Cannabis 1.0” to include smoked cannabis, baked goods, products sometimes manufactured haphazardly; whereas, Next Frontier Biosciences has developed a line of products, called Verra Wellness, which includes topicals, sublingual sprays, and — perhaps most uniquely — nasal sprays.
The company doesn’t make the products itself; that’s done by third-party manufacturer, RMZ Colorado, which is licensed in Colorado to make marijuana-infused goods. Colagiovanni describes Next Frontier Biosciences as “an IP holding company and brand management company.” At its Westminster lab, Colagiovanni is doing R&D work on formulating pills and effervescent tablets, which will eventually contain cannabis. (There’s no cannabis present for research use at Next Frontier’s lab.)
The company’s slogan is “Where Biotech Meets Cannabis.” Co-founder and Chief Scientific Officer Paul Johnson spent “40 years in biotech in nasal drug development, particularly, with over 100 patents to his name — so, a lot of experience in that area,” says Colagiovanni. She adds, “Our scientific team is [made up of] analytical chemists and chemical engineers.”
See more at the Company Week article.